Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute otitis media, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication in adults.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including tertiary care centres and transplant units. The company adheres to stringent quality standards and provides regulatory documentation for export markets.

Clarithromycin is a macrolide antibiotic used to treat infections caused by susceptible bacteria in the respiratory, ear‑nose‑throat, skin and gastrointestinal systems.

- Community‑acquired pneumonia: eradicates the causative bacteria and improves clinical outcomes. - Acute bacterial sinusitis: reduces sinus inflammation and bacterial load. - Acute otitis media: clears infection and relieves ear pain. - Skin and soft‑tissue infections: resolves cellulitis, abscesses and wound infections. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of triple or quadruple regimens.

Clarithromycin may cause a range of adverse reactions, from mild gastrointestinal discomfort to rare but serious events.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes during therapy. - Diarrhea: loose stools that may be watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty. - QT prolongation: cardiac rhythm changes that may lead to arrhythmia. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Clostridioides difficile‑associated colitis: severe diarrhea with abdominal pain. - Stevens‑Johnson syndrome: serious skin and mucous membrane reaction. - Arrhythmias: irregular heartbeats requiring medical attention.

Clarithromycin requires careful use in specific patient populations and clinical situations. - Pregnancy: Category B – use only if benefits outweigh potential risks. - Liver impairment: monitor liver function tests and adjust therapy as needed. - Renal impairment: dose may need adjustment in severe kidney dysfunction. - Concomitant QT‑prolonging drugs: monitor ECG and electrolytes. - Known hypersensitivity: avoid in patients with documented allergy to macrolides. - Store at room temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Clarithromycin can interact with several medicines, altering their effectiveness or safety.

Major Interactions (Avoid): - Cisapride, pimozide, and other drugs with a narrow therapeutic index metabolized by CYP3A4. - Ergot alkaloids: risk of severe vasospasm. - Certain statins (e.g., simvastatin, lovastatin): increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Theophylline: possible increase in plasma concentrations, watch for toxicity.